Get access

Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4′-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry

Authors

  • Britt Jansson,

    Corresponding author
    1. Division of Pharmacokinetics and Drug Therapy, Department of Biopharmaceutical Sciences, Box 591, SE-751 24 Uppsala, Sweden
    • Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE-751 24 Uppsala, Sweden.
    Search for more papers by this author
  • Doaa Elsherbiny,

    1. Division of Pharmacokinetics and Drug Therapy, Department of Biopharmaceutical Sciences, Box 591, SE-751 24 Uppsala, Sweden
    Search for more papers by this author
  • Ulrika S. H. Simonsson

    1. Division of Pharmacokinetics and Drug Therapy, Department of Biopharmaceutical Sciences, Box 591, SE-751 24 Uppsala, Sweden
    Search for more papers by this author

Abstract

A sensitive method using enantiospecific liquid chromatography/tandem mass spectrometry detection for the quantitation of S- and R-mephenytoin as well as its metabolites S- and R-nirvanol and S- and R-4′-hydroxymephenytoin in plasma and urine has been developed and validated. Plasma samples were prepared by protein precipitation with acetonitrile, while urine samples were diluted twice with the mobile phase before injection. The analytes were then separated on a chiral α1-acid glycoprotein (AGP) column and thereafter detected, using electrospray ionization tandem mass spectrometry. In plasma, the lower limit of quantification (LLOQ) was 1 ng/mL for S- and R-4′-hydroxymephenytoin and S-nirvanol and 3 ng/mL for R-nirvanol and S- and R-mephenytoin. In urine, the LLOQ was 3 ng/mL for all compounds. Resulting plasma and urine intra-day precision values (CV) were <12.4% and <6.4%, respectively, while plasma and urine accuracy values were 87.2–108.3% and 98.9–104.8% of the nominal values, respectively. The method was validated for plasma in the concentration ranges 1–500 ng/mL for S- and R-4′-hydroxymephenytoin, 1–1000 ng/mL for S-nirvanol, and 3–1500 ng/mL for R-nirvanol and S- and R-mephenytoin. The validated concentration range in urine was 3–5000 ng/mL for all compounds. By using this method, the metabolic activities of two human drug-metabolizing enzymes, cytochrome P450 (CYP) 2C19 and CYP2B6, were simultaneously characterized. Copyright © 2006 John Wiley & Sons, Ltd.

Ancillary